FCM
TVRD

Frontier Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Frontier Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,975
Closed -$3.58M – 293
2021
Q2 		$3.58M Sell
6,975
-911
-12% -$577K 0.03% 277
2021
Q1 		$6.16M Sell
7,886
-2,578
-25% -$1.76M 0.05% 246
2020
Q4 		$5.7M Buy
10,464
+3,151
+43% +$1.65M 0.04% 255
2020
Q3 		$3.35M Buy
+7,313
New +$4.25M 0.03% 272

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Frontier Capital Management's TVRD Position: Q3 2021 in Review

Frontier Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 6,975 shares — an estimated $3.58M sold.

Frontier Capital Management first reported a position in TVRD in Q3 2020 and held it in 4 quarters. The position peaked at $6.16M in Q1 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Frontier Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Frontier Capital Management sold 6,975 Tvardi Therapeutics shares in Q3 2021, an estimated $3.58M.
  • Frontier Capital Management first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 4 quarters.
  • Frontier Capital Management's Tvardi Therapeutics position peaked at $6.16M in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Frontier Capital Management's 13F filing for Q3 2021, filed 19 Oct 2021.